Pustular Psoriasis

  • Andrew Johnston


Pustular forms of psoriasis are a group of rare, debilitating, and often life-threatening inflammatory skin diseases characterized by episodic skin infiltration of neutrophils, pustule development, erythema and desquamation, which can manifest in the presence or absence of chronic plaque psoriasis. The skin involvement is frequently accompanied by a high-grade fever, fatigue and systemic inflammation. Despite having different genetic and environmental etiologies generalized pustular psoriasis (GPP), acute generalized exanthemous pustulosis (AGEP), palmo-plantar pustulosis (PPP) and acrodermatitis continua of Hallopeau (ACH) are all characterized by a massive influx of neutrophils into the epidermis, thus share some mechanistic aspects. To date, treatments for these diseases have been unsatisfactory with disease recurrence common; however, recent genetic data and ongoing clinical trials with biologic therapies are revealing hitherto unknown mechanisms, substantially improving our understanding and management of these diseases.

Pustular Psoriasis

Psoriasis is one of the most common and well-studied inflammatory skin diseases, affecting about 2% of the population [1]. The pathogenesis of plaque psoriasis (psoriasis vulgaris), involves the interplay of keratinocytes, T cells, antigen-presenting cells and to a limited extent, neutrophils as the central cellular components of the disease [2]. A number of pustular variants of psoriasis have been described, their pustular nature betraying the prominent role of neutrophils in the disease process. Although often categorized as subtypes or variants of psoriasis, as detailed below, these diseases have conspicuous genetic, environmental, temporal, mechanistic, and histological characteristics which set them apart from common plaque psoriasis (Table 11.1). These differences are heightened by the recent discovery of a number of pustular disease-associated genetic loci which have driven great strides in our understanding of the pathogenic mechanisms behind pustular psoriasis.
Table 11.1

Contrasting characteristics of plaque and pustular psoriasis


Plaque psoriasis

Pustular psoriasis


Complex genetics: 80+ risk loci identified


3 loci identified: IL36RN, CARD14, AP1S3


Gradual (plaque), although guttate psoriasis onset is acute (often following streptococcal pharyngitis)

Onset is acute, often with high-grade fever and chills

Systemic signs

Elevated skin and serum cytokines

Markers of systemic inflammation elevated

Effector cells

T cell driven; neutrophils present

Neutrophils predominate


Acanthosis (uniform elongation of the rete ridges), parakeratosis and orthokeratosis, loss of granular layer, pustules can be presentin spinous layer (Munro’s microabscess), upper part of epidermis (spongiform pustules of Kogoj), beneath the normal cornified layer or within the parakeratotic layer (intracorneal pustule)

Widespread intraepidermal or subcorneal pustules in erythrodermic and edematous skin, spongiosis, massive epidermal neutrophil infiltrate eosinophils, apoptotic keratinocytes

Pustular psoriasis is often classified as a variant of plaque psoriasis yet striking clinical, histological and genetic differences suggest that the two diseases have distinct pathogenic mechanisms

Generalized Pustular Psoriasis

Several variants of pustular psoriasis have been described, occurring as either localized or systemic (generalized) diseases. Generalized pustular psoriasis (GPP), also known as acute pustular psoriasis of von Zumbusch, after the disease’s first description in 1910 [3], is a rare (prevalence of 1 in 10,000), debilitating and life-threatening disease, characterized by episodic infiltration of neutrophils into the skin, pustule development, generalized erythema and desquamation (Fig. 11.1, left). The disease manifests as clearly defined, raised bumps on the skin that are filled with pus (pustules). In contrast to plaque psoriasis, the onset of GPP is acute and frequently accompanied by chills, high-grade fever, fatigue and neutrophilia which can be potentially life-threatening and require hospitalization [4, 5]. Cases of GPP can occur either as a distinct entity or are preceded by, concurrent with, or followed by chronic plaque psoriasis, a phenomenon that has confounded the study of the disease [5]. GPP can be difficult to treat, and until recently, therapeutic options have been limited to those that have proven efficacy for plaque psoriasis such as retinoids (acitretin), methotrexate, cyclosporine A, 6-thioguanine, hydroxyurea; however, these drugs typically do not completely control the disease, with resistance to existing treatments and disease recurrence commonly associated with GPP [6]. This shortfall in the efficacy of these treatments likely comes from an incomplete overlap of the pathobiology of plaque psoriasis and pustular forms of psoriasis [7] and there are ongoing efforts to improve our understanding of these disease mechanisms to aid the development of new therapies [7, 8]. Critical to these efforts are recent genetic findings which, as detailed below, have reshaped our understanding and management of these diseases.
Fig. 11.1

Generalized pustular psoriasis (left images), acute generalized exanthematous pustulosis (AGEP, middle), and palmo-plantar pustulosis (PPP, right images). Images courtesy of Dr. Johann E. Gudjonsson (Department of Dermatology, University of Michigan, Ann Arbor, MI, USA)

A second pustular form of psoriasis is a severe cutaneous inflammatory drug reaction, acute generalized exanthematous pustulosis (AGEP). This is characterized by widespread sterile, non-follicular, fine, pinhead-sized pustules arising on edematous and erythemic skin (Fig. 11.1, middle). AGEP has a predilection for the major flexures, and is often accompanied with systemic inflammatory symptoms. AGEP is rare, occurring in one to five individuals per million per year [9], and the vast majority of cases are adverse reactions to medications; However, in rare instances AGEP has also been reported to be induced by triggers as diverse as spider bites, bacterial or viral infections, foods, and herbal remedies [9, 10, 11]. Offending medications include a variety of antibiotics, antimycotics and anticonvulsants. Several of the drugs reported to trigger AGEP are also known triggers of Stevens-Johnson syndrome [11, 12] a cutaneous drug reaction in which cytotoxic CD8+ T cell responses predominate; However, unlike Stevens-Johnson syndrome, no confirmed associations with HLA alleles exist for AGEP patients [13] and cutaneous responses in AGEP are typically much more rapid (24–48 h versus 1–3 weeks) [13]. Notwithstanding, the activation of drug-specific CD4+ and CD8+ T cells is proposed to be involved in the initial triggering of neutrophil activation and infiltration of the skin in AGEP [14]. As with other severe cutaneous inflammatory drug reactions, the identification and withdrawal of the offending drug are the essential first therapeutic steps, with subsequent glucocorticosteroids to induce disease remission. Despite their seemingly divergent initial triggers, to date no clear histological or immunohistochemical differences have been demonstrated between GPP and AGEP, and the recent identification of shared genetic mutations between these diseases strengthens the idea that they share pathological mechanisms and therapeutic targets [15, 16, 17]. Carriage of certain genetic mutations may also influence the disease phenotype [15], suggesting that as the disease allele influences the disease process, further sub-phenotyping based on genetics and clinical features will be necessary to better understand this disease and to optimize effective treatments. Other systemic forms of pustular psoriasis have been described, including impetigo herpetiformis (a form of pustular psoriasis occurring in pregnancy) [18], and annular pustular psoriasis where lesions develop in ring-like, circular forms.

Localized Forms of Pustular Psoriasis

Localized forms of pustular psoriasis include palmo-plantar pustulosis (PPP) and acrodermatitis continua of Hallopeau (ACH), where the disease has a predilection for the palms and soles, or the tips of the fingers and toes, respectively. PPP manifests as cyclic and erupting sterile pustules on the palms and soles, often under a thick cornified layer (Fig. 11.1, right). The pustules may be present on clear skin or erythematous and hyperkeratotic lesions. Despite its restricted anatomical pattern, patients with severe symptoms may have significant pain and be unable to stand, walk or do manual work, thus this disease has a profound impact on quality of life [19, 20]. PPP has a worldwide distribution and is associated with plaque psoriasis in about 20% of cases; PPP, without concomitant plaque psoriasis, has an incidence estimated between 1 and 5 in 10,000 [21, 22]. Onset of the disease occurs mostly between the ages of 20 and 60 years and, unlike plaque psoriasis, has a strong predilection for women [22, 23]. As with GPP, a number of early [24, 25] and more recent [23, 26] genetic observations, together with clinical and epidemiological features have suggested that PPP is an entity distinct from plaque psoriasis [27].

The cause of the disease predilection for the palms and soles is unknown, but these areas are differentiated by the presence of numerous eccrine sweat glands (acrosyringium) which have been implicated in the pathogenesis of PPP [28, 29, 30]. A number of studies found that the majority of their PPP cohort was either current or former tobacco smokers [22, 23, 31]. This led to the suggestion that PPP is an autoimmune reaction induced by tobacco smoking against the acrosyringium and the papillary endothelium [31]. PPP has been associated with tonsillitis, in particular infections with α-streptococci have been implicated in triggering the disease. In support of this, increased numbers of α-streptococci-reactive T cells, have been detected in the tonsils of PPP compared with recurrent tonsillitis patients [32]. Elevations in the frequency of both cutaneous lymphocyte-associated antigen positive (CLA, a molecule expressed by the majority of T cells in the skin) and CCR6 positive T cells have been detected in the tonsils of PPP patients compared with non-PPP (recurrent tonsillitis) patients [32, 33]. Moreover, the abundance of these CLA+ or CCR6+ T cells was reduced in the peripheral blood of these PPP patients in the months following tonsillectomy [32, 33]. These populations are thought to represent streptococci-specific skin-homing T cells, which on entering the skin can initiate an inflammatory reaction after misrecognition of their cognate antigens. This scenario is analogous to that posited for chronic plaque and guttate psoriasis patients, wherein β-hemolytic streptococcus is suspected of initiating the disease, particularly for patients carrying one or two copies of the HLA-Cw*0602 allele [34, 35, 36]. This contrasts with PPP, where no strong class I HLA association is known and α-streptococcus a suspected culprit. The mechanism whereby a bout of streptococcal tonsillitis leads to the elicitation of a chronic skin pustulosis is currently unknown, however tonsillectomy has been anecdotally associated with disease remission. The efficacy of tonsillectomy for PPP has not been properly assessed, yet is regarded as a routine treatment for PPP in Japan [32, 37, 38, 39].

Genetic Clues to Disease Mechanisms in Pustular Psoriasis

Until recently, the etiology and pathogenic mechanisms of pustular psoriasis were unknown, which critically stalled the development of specific and effective treatments. During the last decade, the situation has radically changed with the identification of inherited mutations in three genes each of which, through altered function of their respective proteins, cause inflammatory mechanisms to be dysregulated, leading to the development of neutrophilic skin disease.

The first gene found to be associated with GPP is IL36RN [40, 41]. These seminal observations brought IL-36, a cytokine which at the time was more of a curiosity than a critical and disease-inducing cytokine, into the limelight. The GPP-associated missense mutations in IL36RN affect the structure and function of the IL-36 receptor antagonist (IL-36Ra). Loss of functional IL-36Ra leads to unrestricted IL-36 activity, as evidenced by induction of IL-1β, IL-6, and CXCL8 production, and neutrophil infiltration of skin [40, 41]. Since these initial observations, mutations in IL36RN have been identified in numerous studies of GPP with and without concomitant plaque psoriasis, as well as cases of AGEP [15, 16, 17, 42], but not PPP [17, 23, 43], suggesting different a different etiology for PPP.

The three isoforms of IL-36 exist: IL-36α, β and γ, which form a trio of pro-inflammatory IL-1-like cytokines that are overexpressed in lesions of plaque psoriasis [44, 45, 46], GPP [7], and AGEP [8], where they can drive keratinocyte inflammatory responses [44], synergize with other pro-inflammatory cytokines [44, 47], and promote dendritic cell activation [48, 49]. The effects of IL-36 on skin have been modeled in mice [44, 45], where the transgenic expression of IL-36α in murine epidermis led to epidermal thickening, hyperkeratosis, mixed inflammatory cell infiltrate, and elevated chemokine expression [45]. Backcrossing to an IL36RN-deficient mouse resulted in more severe skin lesions, reflecting the effect of nonsense IL36RN mutations in GPP. This phenotype was partly reversed by the use of a neutrophil-depleting antibody, suggesting a causative role for neutrophils in this IL-36α-induced skin hyperplasia. This is supported by our own observations that subcutaneous administration of IL-36α to mice induces acanthosis and prominent neutrophilic infiltration [48]. IL-36 expression is also elevated in the skin of psoriasiform KC-Tie2 mice [44] and during imiquimod-induced skin inflammation [44, 50]. One of the early features of imiquimod-treated mouse skin is neutrophil infiltration, and the inflammatory phenotype is ablated in IL-36 receptor deficient mice [50] adding further support for a neutrophil/IL-36 axis as a central driver in the development of skin inflammation in GPP. Like their IL-1 family counterparts IL-1β, IL-18 and IL-33, the IL-36 cytokines require post-translational N-terminal peptide cleavage for activity [51] and it was recently demonstrated that IL-36 cleavage could be carried out by the neutrophil serine proteases elastase and cathepsin G [7, 52] as well as keratinocyte-derived cathepsin S [53]. Cathepsin S is strongly upregulated in psoriasis lesions, likely by the synergistic actions of TNF and IFN-γ, and, unlike elastase and cathepsin G, cathepsin S has been demonstrated to cleave IL-36γ into its most potent form [53]. Interestingly, these processes appear to be regulated by the activities of endogenous protease inhibitors expressed by the keratinocytes of psoriasis skin lesions, indicating the presence of a potential feedback inhibitory mechanism to restrain IL-36 driven inflammation [7].

Mutations in IL36RN have been shown to account for between 46 and 82% of cases of GPP without associated plaque psoriasis [54, 55]. The proportion of IL36RN mutant carriage is much lower (10–17%) in cases of GPP with concomitant plaque psoriasis [56], supporting the idea that divergent pathogenic mechanisms may be active in the two diseases. A recent meta-analysis of 233 GPP cases revealed that carriage of one or two IL36RN mutant alleles conferred a more severe clinical phenotype with an earlier age of onset and increased risk of systemic inflammation than non-carriage [56]. Moreover, a gene-dosage effect was also evident as homozygous carriers had an earlier age of onset than heterozygotes.

Mutations in AP1S3 affecting the structure and function of the AP-1 complex subunit σ1C have been identified in ACH [57], GPP and PPP [26] patients. AP-1 is a member of the adaptor protein (AP) family which is a group of cytosolic heterotetrameric complexes that direct the assembly and trafficking of small transport vesicles [58]. Each of the five known complexes (AP-1, AP-2, AP-3, AP-4, and AP-5) is active in a distinct subcellular compartment, where it mediates the delivery of transmembrane proteins to specific target organelles [59]. AP-1 is involved in the transport of cargo between the trans-Golgi network and the endosomes, a process that requires the formation of specialized clathrin-coated vesicles [58]. Similar to other AP complexes, AP-1 consists of two large (γ1 and β1), one medium (μ1), and one small (σ1) subunit. The σ1 subunit exists in three forms, σ1A, σ1B, and σ1C, encoded by AP1S1, AP1S2, and AP1S3 respectively. Of particular interest here, the σ subunit stabilizes the tetrameric complex and thus non-synonymous mutations in AP1S genes are predicted to destabilize the entire AP-1 complex disrupting protein transport [57]. The two pustular psoriasis-associated AP1S3 mutations described (p.Phe4Cys and p.Arg33Trp) lead to loss of AP1S3 function by reducing the stability of AP1-σ1C and by disrupting the interaction between the AP1-σ1C and AP1-μ1A subunits, respectively [26, 57]. Loss of AP1S3 function was found to result in reduced autophagy, a process shown to modulate NF-κB signaling by degrading p62, an adaptor molecule which binds TRAF6 leading to NF-κB activation. Carriage of mutant alleles resulted in p62 accumulation, and enhanced IL-1β, IL-8 and IL-36γ cytokine production in response to Toll-like receptor or IL-1R stimulation by keratinocytes from patients carrying AP1S3 mutations [26].

Mutations in CARD14 leading to structural and functional changes in caspase recruitment family member 14 (CARD14, previously known as CARMA2), have been associated with plaque psoriasis [60, 61], GPP [60, 62, 63], PPP [23], and pityriasis rubra pilaris, a papulosquamous condition phenotypically related to psoriasis [64, 65]. CARD14 is a member of the CARD-containing membrane-associated guanylate kinase (MAGUK) protein (CARMA) family of scaffold proteins. The other two members, CARD11 (CARMA1) and CARD10 (CARMA3) are critical for the activation of NF-κB in response to antigen and G-protein-coupled receptor stimulation respectively. On activation, CARD14 forms a signaling complex with BCL10 and MALT1, leading to activation of NF-κB, JNK, and p38 MAP kinase pathways [66, 67, 68]. Thirty-two CARD14 mutations have been described for plaque and pustular psoriasis [69] with the majority of the variants affecting the CARD or coiled-coil domains of the protein. These disease-associated mutations alter the structure of an inhibitory domain which normally keeps CARD14 activity in check, thus bypassing the need for an activating stimulus [62, 66, 68]. The psoriasis-associated CARD14 mutant proteins induce spontaneous formation of CARD14-BCL10-MALT1 complexes, which triggers MALT1 to promote inflammation in two key ways: first, by initiating pro-inflammatory signal transduction via its scaffold function; second, as a paracaspase MALT1 has the ability to cleave A20, CYLD, and RelB, three negative regulators of NF-κB, thus disabling feedback inhibition and further driving the inflammatory response. Like AP1S3 [26], CARD14 appears to be preferentially expressed by epidermal keratinocytes, and also to a lesser extent endothelial cells [60, 70]. CARD14 expression is strongly upregulated in psoriasis skin lesions [60], particularly in the upper epidermis which is also the zone where many NF-κB response genes (e.g., IL-36, CCL20, CXCL1, CXCL8) are overexpressed in lesional psoriasis skin. This pattern of AP1S3 and CARD14 tissue expression likely explains why these gain of function mutations lead to inflammatory skin disease.

Common, or at least overlapping, mechanisms may underlie the pathology of these diseases. Different gene mutations (IL36RN, AP1S3, CARD14) leading to activation of different molecules (IL-36R, p62, MALT1) which feed into common, or at least overlapping, signaling pathways (NF-κB, MAP kinases) to drive unwarranted and dysregulated inflammatory responses (Fig. 11.2). In some cases a single dominant mutation may be sufficient to cause disease as is the case with CARD14 where mutations may be sufficient to cause disease (at least without contributions from IL36RN mutations or HLA-Cw*0602 carriage [23, 60]). Likewise, the initial study on AP1S3 focused on finding mutations in a group of ACH patients who had been typed as non-carriers of IL36RN and CARD14 mutations [57]. However there are indications of epistasis between mutant loci: an individual carrying deleterious mutations in AP1S3 and IL36RN was found to have a much more severe disease phenotype than her sibling carrying only the IL36RN mutation [26]. As the gain-of-function mutations in CARD14, and loss-of-function AP1S3 and IL36RN mutants all result in a net increase in NF-κB activity, it is not unexpected to see additive effects resulting from the carriage of multiple disease alleles (Fig. 11.2).
Fig. 11.2

Pustular psoriasis-associated IL36RN, AP1S3, and CARD14 mutations activate overlapping pathways leading to inflammatory gene expression, chemokine production and neutrophil infiltration. IL36RN mutations giving rise to loss of function of the IL-36 receptor antagonist (IL-36Ra) lead to unrestrained IL-36 activity at the IL-36 receptor. This signal is transduced via NF-κB driving inflammatory cytokine (IL-1, IL-36, TNF) and chemokine (CXCL1, CXCL2, CXCL8, CCL20) production, drawing neutrophils into the skin. Mutations in AP1S3 result in loss of AP-1 function and defective autophagy, leading to an accumulation of the adaptor protein p62, which drives cellular inflammatory responses downstream of Toll-like (e.g., TLR2/4) and cytokine receptors (including IL-17, TNF, IL-1, IL-36), again signaling via TRAF6 and the NF-κB pathway. Lastly, the disease-associated mutations in CARD14 result in structural alterations in the protein’s CARD or coiled-coil domains leading to loss of an inhibitory motif and spontaneous formation of CARD14-BCL10-MALT1 complexes that drive NF-κB activity. This is likely augmented by the paracaspase activity of MALT1 which can degrade a number of negative regulators of NF-κB signaling such as the deubiquitinases A20 and CYLD

Emerging Treatments for Pustular Psoriasis

Pustular psoriasis utilizes signaling pathways both overlapping and separate from plaque psoriasis, and because of their efficacy in moderate-severe plaque psoriasis, a number of therapies specifically targeting cytokines are in use for GPP. Several reports describe the use of anakinra, an IL-1 receptor antagonist [71, 72, 73] or canakinumab, a human monoclonal antibody targeted at IL-1β [74], to treat GPP. Anakinra appears to induce a rapid normalization of systemic inflammatory symptoms followed by improvement of the pustular skin eruption. The responses to IL-1 receptor inhibition in the skin tend to be incomplete however, with erythema and hyperkeratosis remaining in some cases, which suggests that IL-1 is not playing a central role in GPP but acts in a positive feedback loop inducing and being induced by IL-36 [44]. The relevance of using IL-1 receptor antagonism to tackle a disease which may be primarily driven by deviations in IL-36 signaling, particularly when IL36RN mutations are present, has recently been questioned [75]. However, clinical trials are ongoing in the UK (APRICOT) and USA (NIH NCT01794117) assessing the efficacy of anakinra and PPP and pustular skin diseases (including PPP) respectively. The premise for these trials is the effectiveness of anakinra for treatment of diseases caused by IL-1RA deficiency and the elevated IL-1 and IL-36 activity in observed PPP. The outcome of these trials will be interesting given the reported lack of genetic associations between PPP and IL1RN and IL36RN mutations [17, 23, 43].

TNF-α is a central mediator in chronic plaque psoriasis as evidenced by the effectiveness of therapies that block TNF-α activity. Of the three TNF biologics in use for plaque psoriasis, infliximab has most commonly been used for GPP [76, 77] and as such has become one of the recommended treatment options for severe acute GPP despite the lack of adequate clinical trials [6]. Infliximab has been reported to have a rapid effect, with systemic inflammation and skin pustules starting to recede in as little as 2 days from the first infusion. In this context, the efficacy of infliximab likely stems from the rapid availability of the drug following infusion, and its inhibition of the synergy between TNF and multiple inflammatory cytokines including IL-36, IL-17A, IL-1β [44, 47, 78, 79].

Given the plethora of recent studies highlighting the effectiveness of targeting of IL-17A in plaque psoriasis, this approach has now also been tested with success for treating GPP. The notion that IL-17 may have a prominent role in pustular psoriasis is not only supported by the efficacy of blocking IL-17, and the presence of increased tissue IL-17A [80], skin-homing Th17 T cells [81], IL-17+ neutrophils [82], and strong IL-17A signatures in the lesions [7, 8], but also the clinical observations of severe pustular flare after sudden discontinuation of IL-17 axis suppression by brodalumab in psoriasis patients [83]. IL-17 is a key cytokine in the induction of chemokine-mediated neutrophil infiltration of skin [84], and neutrophils are an obvious and central mechanistic component of pustular diseases. Not only do neutrophils express IL-17 [82, 85, 86] but they have also been shown to respond to IL-17A [87] as they express both prerequisite receptor subunits for IL-17A response. Secukinumab, a biologic targeting IL-17A, was recently shown to rapidly improve both systemic symptoms and the skin disease in GPP patients [88, 89, 90]. Likewise brodalumab, a biologic targeting the IL-17 receptor A chain, was also shown to induce clinical improvement in 11 out of 12 GPP patients [91]. Given the encouraging findings from biologics targeting IL-17, there are now several ongoing trials examining inhibition of IL-23, a cytokine thought to act upstream of IL-17, as a master regulator of IL-17 expression by T cells [92, 93] and neutrophils [87]. Both guselkumab (NIH NCT02343744) and risankizumab (NIH NCT03022045) are biologics targeting IL-23p19 under test for treating GPP. Given the seemingly central role of the IL-36/IL-36R system in GPP, supported by a glut of genetic and mechanistic data, this is surely an attractive target for the development of new therapies for GPP [94, 95].

PPP is a very difficult disease to treat and is commonly recalcitrant to existing therapeutic options, a situation that is confounded by the paucity of robust clinical trials of new medications. As such, therapeutic recommendations have often relied on case reports, thus less rigorous data is currently available for the efficacy of biologics in PPP. Unlike GPP, reports on the usage of anti-TNF biologics in PPP have revealed only modest to poor responses with all three of the TNF biologics used for plaque psoriasis [96, 97, 98]. Moreover there exist several reports of new onset PPP following anti-TNF treatment of other diseases [99, 100, 101, 102, 103]. Studies using ustekinumab, an antibody directed at IL-12p40 (a shared subunit of IL-12 and IL-23), for PPP have also generated equivocal results [104, 105, 106, 107]. Much more promising data have emerged for two of the IL-17 biologics (secukinumab and ixekizumab), the use of which is supported by the detection of elevated levels of IL-17 [108, 109] and enrichment of IL-17 signature genes in PPP lesions [8]. A recent study of secukinumab for moderate to severe PPP demonstrated a 50% improvement in disease severity and significant improvements in quality of life scores [90]. Given that increased IL-23 has been detected in PPP lesions [109, 110], inhibition of IL-23p19 may also be an effective approach for PPP therapy.

Concluding Remarks

The discovery of mutations in IL36RN, CARD14 and AP1S3 that lead to dysregulated inflammation have increased enormously our understanding of pustular psoriasis over the last decade; However, several pieces of the puzzle remain to be revealed. It is likely that carriage of a mutant allele in itself is not enough for disease initiation: many pustular psoriasis patients have their first episode of the disease as adults, despite being lifelong mutant allele carriers, and patients can be heterozygous at disease loci, suggesting that either a yet to be identified second disease locus, or environmental trigger may be necessary to precipitate the disease. The co-occurrence of plaque psoriasis, GPP, PPP, or AGEP has confounded the genetic and mechanistic study of these diseases, which highlights the importance of clear phenotyping and sequential screening of disease-associated genes to increase the power to detect new pathogenic mutations and thus shed more light on the disease mechanisms. Thus, despite recent major advances in the study and treatment of pustular skin diseases, there remain key genetic, environmental and mechanistic pieces to be identified to solve these puzzling and difficult to treat diseases.


  1. 1.
    Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2012;133:377–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8).Google Scholar
  3. 3.
    von Zumbush L. Psoriasis and pustuloses exanthem. Arch Derm Syph. 1910;99:335–46.CrossRefGoogle Scholar
  4. 4.
    Mengesha YM, Bennett ML. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol. 2002;3:389–400.PubMedCrossRefGoogle Scholar
  5. 5.
    Gudjonsson JE, Elder JT. Psoriasis (Chapter 18). In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine, vol. 1. 8th ed. New York: McGraw-Hill Medical; 2012.Google Scholar
  6. 6.
    Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:279–88.PubMedCrossRefGoogle Scholar
  7. 7.
    Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2016;140(1):109–20.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Liang Y, Xing X, Beamer MA, et al. Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders. J Allergy Clin Immunol. 2017;139(4):1217–27.PubMedCrossRefGoogle Scholar
  9. 9.
    Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)—a clinical reaction pattern. J Cutan Pathol. 2001;28:113–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73:843–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157:989–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.PubMedCrossRefGoogle Scholar
  13. 13.
    Paulmann M, Mockenhaupt M. Severe drug hypersensitivity reactions: clinical pattern, diagnosis, etiology and therapeutic options. Curr Pharm Des. 2016;22:6852–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Schmid S, Kuechler PC, Britschgi M, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol. 2002;161:2079–86.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol. 2013;133:1904–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Nakai N, Sugiura K, Akiyama M, Katoh N. Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation. JAMA Dermatol. 2015;151:311–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Setta-Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133:1366–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Oumeish OY, Parish JL. Impetigo herpetiformis. Clin Dermatol. 2006;24:101–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Chung J, Callis Duffin K, Takeshita J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71:623–32.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49:271–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Hellgren L, Mobacken H. Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis. Acta Derm Venereol. 1971;51:284–8.PubMedGoogle Scholar
  22. 22.
    Brunasso AM, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol. 2013;168:1243–51.PubMedCrossRefGoogle Scholar
  23. 23.
    Mossner R, Frambach Y, Wilsmann-Theis D, et al. Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European patients. J Invest Dermatol. 2015;135:2538–41.PubMedCrossRefGoogle Scholar
  24. 24.
    Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120:627–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Mossner R, Kingo K, Kleensang A, et al. Association of TNF-238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol. 2005;124:282–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Mahil SK, Twelves S, Farkas K, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136:2251–9.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007;156:258–62.PubMedCrossRefGoogle Scholar
  28. 28.
    Krieg PH, Bacharach-Buhles M, el-Gammal S, Altmeyer P. The pustule in palmoplantar psoriasis: transformed vesicle or mature microabscess? A three-dimensional study. Dermatology. 1992;185:104–12.PubMedCrossRefGoogle Scholar
  29. 29.
    Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138:390–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Murakami M, Ohtake T, Horibe Y, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol. 2010;130:2010–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Hagforsen E, Awder M, Lefvert AK, Nordlind K, Michaelsson G. Palmoplantar pustulosis: an autoimmune disease precipitated by smoking? Acta Derm Venereol. 2002;82:341–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Yoshizaki T, Bandoh N, Ueda S, et al. Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris. Clin Exp Immunol. 2009;157:71–82.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Nozawa H, Kishibe K, Takahara M, Harabuchi Y. Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP). Clin Immunol. 2005;116:42–53.PubMedCrossRefGoogle Scholar
  34. 34.
    Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, Gudjonsson JE, Johnston A. Psoriasis—as an autoimmune disease caused by molecular mimicry. Trends Immunol. 2009;30:494–501.PubMedCrossRefGoogle Scholar
  35. 35.
    Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: a prospective case series. J Am Acad Dermatol. 2016;75:889–96.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol. 2012;188:5160–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Koshiba S, Ichimiya S, Nagashima T, et al. Tonsillar crypt epithelium of palmoplantar pustulosis secretes interleukin-6 to support B-cell development via p63/p73 transcription factors. J Pathol. 2008;214:75–84.CrossRefPubMedGoogle Scholar
  38. 38.
    Yokoyama M, Hashigucci K, Yamasaki Y. Effect of tonsillectomy in patients with pustulosis palmaris et plantaris. Acta Otolaryngol. 2004;124:1109–10.CrossRefPubMedGoogle Scholar
  39. 39.
    Ozawa A, Ohkido M, Haruki Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol. 1999;26:141–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–8.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89:432–7.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Navarini AA, Simpson MA, Borradori L, Yawalkar N, Schlapbach C. Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis. JAMA Dermatol. 2015;151:452–3.PubMedCrossRefGoogle Scholar
  43. 43.
    Takahashi T, Fujimoto N, Kabuto M, Nakanishi T, Tanaka T. Mutation analysis of IL36RN gene in Japanese patients with palmoplantar pustulosis. J Dermatol. 2017;44:80–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186:2613–22.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007;204:2603–14.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Debets R, Timans JC, Homey B, et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol. 2001;167:1440–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131:2428–37.PubMedCrossRefGoogle Scholar
  48. 48.
    Foster AM, Baliwag J, Chen CS, et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol. 2014;192:6053–61.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Mutamba S, Allison A, Mahida Y, Barrow P, Foster N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur J Immunol. 2012;42:607–17.PubMedCrossRefGoogle Scholar
  50. 50.
    Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 2012;122:3965–76.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36{alpha}, IL-36{beta} and IL-36{gamma}) or antagonist (IL-36Ra) activity. J Biol Chem. 2011;286:42594–602.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Henry CM, Sullivan GP, Clancy DM, Afonina IS, Kulms D, Martin SJ. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 2016;14:708–22.PubMedCrossRefGoogle Scholar
  53. 53.
    Ainscough JS, Macleod T, McGonagle D, et al. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36gamma. Proc Natl Acad Sci U S A. 2017;114(13):E2748–57.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Korber A, Mossner R, Renner R, et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol. 2013;133:2634–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133:2514–21.PubMedCrossRefGoogle Scholar
  56. 56.
    Hussain S, Berki DM, Choon SE, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135:1067–1070 e1069.PubMedCrossRefGoogle Scholar
  57. 57.
    Setta-Kaffetzi N, Simpson MA, Navarini AA, et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet. 2014;94(5):790–7.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Robinson MS. Adaptable adaptors for coated vesicles. Trends Cell Biol. 2004;14:167–74.PubMedCrossRefGoogle Scholar
  59. 59.
    Nakatsu F, Hase K, Ohno H. The role of the clathrin adaptor AP-1: polarized sorting and beyond. Membranes (Basel). 2014;4:747–3.CrossRefGoogle Scholar
  60. 60.
    Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90:784–95.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Jordan CT, Cao L, Roberson ED, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet. 2012;90:796–808.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Berki DM, Liu L, Choon SE, et al. Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris. J Invest Dermatol. 2015;135:2964–70.PubMedCrossRefGoogle Scholar
  63. 63.
    Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol. 2014;134:1755–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Li Q, Jin Chung H, Ross N, et al. Analysis of CARD14 polymorphisms in pityriasis rubra pilaris: activation of NF-kappaB. J Invest Dermatol. 2015;135:1905–8.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Fuchs-Telem D, Sarig O, van Steensel MA, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91:163–70.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Afonina IS, Van Nuffel E, Baudelet G, et al. The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes. EMBO Rep. 2016;17:914–27.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Scudiero I, Zotti T, Ferravante A, Vessichelli M, Vito P, Stilo R. Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF-kappaB activation and endoplasmic reticulum stress-induced cell death. J Cell Physiol. 2011;226:3121–31.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Howes A, O’Sullivan PA, Breyer F, et al. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-kappaB activation. Biochem J. 2016;473:1759–68.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Van Nuffel E, Schmitt A, Afonina IS, Schulze-Osthoff K, Beyaert R, Hailfinger S. CARD14-mediated activation of paracaspase MALT1 in keratinocytes: implications for psoriasis. J Invest Dermatol. 2017;137:569–75.PubMedCrossRefGoogle Scholar
  70. 70.
    Harden JL, Lewis SM, Pierson KC, et al. CARD14 expression in dermal endothelial cells in psoriasis. PLoS One. 2014;9:e111255.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Rossi-Semerano L, Piram M, Chiaverini C, De Ricaud D, Smahi A, Kone-Paut I. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics. 2013;132:e1043–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Huffmeier U, Watzold M, Mohr J, Schon MP, Mossner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Viguier M, Guigue P, Pages C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010;153:66–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Skendros P, Papagoras C, Lefaki I, et al. Successful response in a case of severe pustular psoriasis after interleukin-1beta inhibition. Br J Dermatol. 2017;176:212–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Tauber M, Viguier M, Le Gall C, Smahi A, Bachelez H. Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist? Br J Dermatol. 2014;170:1198–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol. 2002;47:796–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol. 2002;41:449–52.PubMedCrossRefGoogle Scholar
  78. 78.
    Johnston A, Guzman AM, Swindell WR, Wang F, Kang S, Gudjonsson JE. Early tissue responses in psoriasis to the antitumour necrosis factor-alpha biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br J Dermatol. 2014;171:97–107.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677–87.PubMedCrossRefGoogle Scholar
  80. 80.
    Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304:465–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Teraki Y, Tanaka S, Hitomi K, Izaki S. A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis. Br J Dermatol. 2010;163:1347–51.PubMedCrossRefGoogle Scholar
  82. 82.
    Kakeda M, Schlapbach C, Danelon G, et al. Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Arch Dermatol Res. 2014;306:933–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Khemis A, Cavalie M, Montaudie H, Lacour JP, Passeron T. Rebound pustular psoriasis after brodalumab discontinuation. Br J Dermatol. 2016;175:1065–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717–4.PubMedCrossRefGoogle Scholar
  85. 85.
    Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490–500.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Keijsers RR, Hendriks AG, van Erp PE, et al. In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORgammat and IL-17. J Invest Dermatol. 2014;134:1276–84.PubMedCrossRefGoogle Scholar
  87. 87.
    Taylor PR, Roy S, Leal SM Jr, et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORgammat and dectin-2. Nat Immunol. 2014;15:143–51.PubMedCrossRefGoogle Scholar
  88. 88.
    Bohner A, Roenneberg S, Eyerich K, Eberlein B, Biedermann T. Acute generalized pustular psoriasis treated with the IL-17A antibody secukinumab. JAMA Dermatol. 2015;152(4):482–4.CrossRefGoogle Scholar
  89. 89.
    Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011–7.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76:70–80.PubMedCrossRefGoogle Scholar
  91. 91.
    Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese brodalumab study g. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741–51.PubMedCrossRefGoogle Scholar
  92. 92.
    Di Meglio P, Nestle FO. The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep. 2010;2:40.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Langrish CL, McKenzie BS, Wilson NJ, de Waal MR, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev. 2004;202:96–105.PubMedCrossRefGoogle Scholar
  94. 94.
    Wolf J, Ferris LK. Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: a patent evaluation of WO2013074569. Expert Opin Ther Pat. 2014;24:477–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Gunther S, Sundberg EJ. Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol. 2014;193:921–30.PubMedCrossRefGoogle Scholar
  96. 96.
    Bissonnette R, Poulin Y, Guenther L, Lynde CW, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25:1402–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol. 2008;7:940–6.PubMedGoogle Scholar
  98. 98.
    Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147:429–36.PubMedCrossRefGoogle Scholar
  99. 99.
    Tresh A, Smith VH, Parslew RA. Behcet’s syndrome treated with infliximab, which caused a palmoplantar pustulosis, subsequently maintained on low-dose etanercept. Libyan J Med. 2012; 7.Google Scholar
  100. 100.
    Capkin E, Karkucak M, Yayli S, Aydin Capkin A, Tosun M. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis. J Clin Rheumatol. 2011;17:293–4.PubMedCrossRefGoogle Scholar
  101. 101.
    Wermuth J, Kind F, Steuerwald M. Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn’s sacroiliitis. Clin Gastroenterol Hepatol. 2009;7:A28.PubMedCrossRefGoogle Scholar
  102. 102.
    Ortiz Salvador JM, Cubells Sanchez L, Subiabre Ferrer D. Palmoplantar pustulosis by adalimumab in a patient with Crohn disease. Med Clin (Barc). 2016;147:565.CrossRefGoogle Scholar
  103. 103.
    Rallis E, Korfitis C, Stavropoulou E, Papaconstantis M. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a ‘class effect’ of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction? J Dermatolog Treat. 2010;21:3–5.PubMedCrossRefGoogle Scholar
  104. 104.
    Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163:1116–8.PubMedCrossRefGoogle Scholar
  105. 105.
    Au SC, Goldminz AM, Kim N, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat. 2013;24:179–87.PubMedCrossRefGoogle Scholar
  106. 106.
    Buder V, Herberger K, Jacobi A, Augustin M, Radtke MA. Ustekinumab in the treatment of palmoplantar pustular psoriasis—a case series of nine patients. JDDG. 2016;14:1108–13.PubMedCrossRefGoogle Scholar
  107. 107.
    Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016;152:825–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20:845–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 2014;28:1298–305.PubMedCrossRefGoogle Scholar
  110. 110.
    Lillis JV, Guo CS, Lee JJ, Blauvelt A. Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. Arch Dermatol. 2010;146:918–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of MichiganAnn ArborUSA

Personalised recommendations